Abbott Laboratories' Implied Fair Value Estimate Edges Higher Amid Legal Wins and Exact Sciences Deal Talk.

Abbott Laboratories' implied fair value estimate has nudged higher to $144.75, driven by its medical devices momentum and the pending Exact Sciences acquisition. Analysts have mixed views, with Bernstein lifting its target to $154, Goldman Sachs trimming its target to $152, and Evercore ISI maintaining an Outperform rating with a $142 target. The company has seen legal wins, including a key case dismissal in its infant formula litigation, which analysts view as positive for reducing legal overhang.